The HIMALAYA Study

Prof Dr Bruno Sangro from the University of Navarra, Spain, presents the updated Phase III HIMALAYA study analysis. The study evaluated the efficacy and safety of the STRIDE regimen, consisting of a single priming dose of tremelimumab plus durvalumab, compared to sorafenib in patients with unresectable hepatocellular carcinoma. Prof Dr Sangro discusses the improved overall survival observed with the STRIDE regimen and durvalumab monotherapy, as well as the safety findings over a four-year follow-up period. These findings provide important insights into the treatment of this challenging form of cancer.

With the educational support of: